Former USTR Official: USMCA Doesn’t Stop Changes To U.S. Biologics Law

/ August 27, 2019 at 3:40 PM
Ratifying the U.S.-Mexico-Canada Agreement would not impede Congress from reducing the exclusivity period for biologics, according to a former Obama administration trade official. Miriam Sapiro, a former acting and deputy U.S. Trade Representative in the Obama administration, in a memo for the Pass USMCA Coalition, said the United States could amend USMCA if it reduced the exclusivity biologics period. Some House Democrats have demanded USTR renegotiate USMCA’s requirement for an exclusivity period for biologics of at least 10 years, arguing...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.